Results: NSCLC patients with overexpression of S100A4 had a worse prognosis than patients with low expression of S100A4 (HR = 1.77, 95% CI: 1.55–2.02, P<0.001). This evidence concerns the gene S100A4 and non-small cell lung carcinoma.